Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus

Alkagiet, Stelina; Τζιόμαλος, Κωνσταντίνος

doi:10.4239/wjd.v11.i5.150

Cited by 1 publication

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that a relatively novel group of anti-diabetic agents, the SGLT2 inhibitors, have been shown to attenuate hyperglycemia-induced cardiac dysfunction in lipodystrophic mice[ 43 ]. In concordance, they exert a cardioprotective effect manifested by improved systolic function, decreased fibrosis and reduced inflammation in At II infusion-induced cardiomyopathy in diabetic mice[ 44 ], elucidating the beneficial effects of SGLT2 inhibitors observed in human studies[ 45 ]. Mechanisms by which SGLT2 inhibition mitigates DCM and HF in general is an increase in natriuresis, osmotic diuresis, plasma volume contraction, reduction of blood pressure and arterial stiffness and lastly, by providing highly energy-efficient substrates for cardiac metabolism, such as β-hydroxybutyrate[ 43 , 45 ].…”

Section: Pathophysiology Of Diabetic Cardiomyopathymentioning

confidence: 99%

Role of novel biomarkers in diabetic cardiomyopathy

Kumrić¹,

Kurir²,

Borovac³

et al. 2021

WJD

View full text Add to dashboard Cite

Diabetic cardiomyopathy (DCM) is commonly defined as cardiomyopathy in patients with diabetes mellitus in the absence of coronary artery disease and hypertension. As DCM is now recognized as a cause of substantial morbidity and mortality among patients with diabetes mellitus and clinical diagnosis is still inappropriate, various expert groups struggled to identify a suitable biomarker that will help in the recognition and management of DCM, with little success so far. Hence, we thought it important to address the role of biomarkers that have shown potential in either human or animal studies and which could eventually result in mitigating the poor outcomes of DCM. Among the array of biomarkers we thoroughly analyzed, long noncoding ribonucleic acids, soluble form of suppression of tumorigenicity 2 and galectin-3 seem to be most beneficial for DCM detection, as their plasma/serum levels accurately correlate with the early stages of DCM. The combination of relatively inexpensive and accurate speckle tracking echocardiography with some of the highlighted biomarkers may be a promising screening method for newly diagnosed diabetes mellitus type 2 patients. The purpose of the screening test would be to direct affected patients to more specific confirmation tests. This perspective is in concordance with current guidelines that accentuate the importance of an interdisciplinary team-based approach.

show abstract